HOTHHoth Therapeutics, Inc.

Nasdaq hoththerapeutics.com


$ 0.94 $ 0.00 (-0.17 %)    

Friday, 14-Jun-2024 15:39:55 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 0.96
$ 0.95
$ 0.93 x 100
$ 0.00 x 0
$ 0.94 - $ 0.96
$ 0.90 - $ 3.37
60,523
na
4.69M
$ 1.00
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-29-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-16-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-13-2020 03-31-2020 10-Q
18 03-02-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 04-01-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hoth-therapeutics-and-wise-systems-international-srl-announces-joint-development-to-utilize-artificial-intelligence-for-drug-discovery-nvidia-bionemo-generative-ai-platform-will-be-used-to-accelerate-the-training-of-models-on-proprietary-data

Nvidia BioNeMo generative AI platform will be used to accelerate the training of models on proprietary dataNEW YORK, June 10, 2...

 hc-wainwright--co-reiterates-buy-on-hoth-therapeutics-maintains-4-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $4 pr...

 ef-hutton-maintains-buy-on-hoth-therapeutics-raises-price-target-to-7

EF Hutton analyst Tim Moore maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and raises the price target from $6.5 to $7.

 why-peraso-shares-are-trading-lower-by-over-23-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected four...

 why-is-alzheimers-focused-hoth-therapeutics-stock-trading-higher-on-tuesday

Hoth Therapeutics reveals preclinical findings on HT-ALZ, a potential Alzheimer's therapeutic targeting the Substance P/Neu...

Core News & Articles
Market-Moving News for March 19th
03/19/2024 12:41:16

CERS: 64% | Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; S...

 hoth-therapeutics-announces-data-in-completed-study-of-alzheimers-disease-pre-clinical-treatment-with-ht-alz

HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer&#...

 hoth-therapeutics-engages-altasciences-to-perform-study-for-ht-kit-cancer-fighting-therapeutic

Hoth's HT-KIT has received FDA Orphan Drug Status and Continues to Show Positive Study Results in Treating Mast Cell-Derive...

 hc-wainwright--co-initiates-coverage-on-hoth-therapeutics-with-buy-rating-announces-price-target-of-4

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Hoth Therapeutics (NASDAQ:HOTH) with a Buy rating a...

 hoth-therapeutics-received-fda-approval-to-expand-ht-001-clinical-trial

Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics

 on-january-8-2024-hoth-therapeutics-filed-a-patent-application-with-the-us-patent-and-trademark-office-for-the-use-of-a-therapeutic-for-weight-loss-and-the-side-effects-associated-with-certain-weight-loss-therapeutics

On January 8, 2024 Hoth Therapeutics filed a patent application with the U.S. Patent and Trademark Office ("USPTO") for...

 why-hoth-therapeutics-shares-are-rising-today

Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares are trading higher after the company announced the expansion of its FDA-cleared f...

 hoth-therapeutics-announces-expansion-of-fda-cleared-first-in-human-clinical-trial-for-cancer-patients-of-ht-001-at-university-of-miami-for-the-treatment-of-skin-toxicities-associated-with-egfri-treatments

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has received appro...